PSA levels typically have correlated with prostate biopsy results in the detection of prostate cancer, but that correlation no longer exists for men with a normal prostate exam, suggest results of a study published online in Cancer. The study suggests that improved biopsy techniques make PSA less useful in prostate cancer screening.
PSA levels typically have correlated with prostate biopsy results in the detection of prostate cancer, but that correlation no longer exists for men with a normal prostate exam, suggest results of a study published online in Cancer. The study suggests that improved biopsy techniques make PSA less useful in prostate cancer screening.
Researchers at the New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, performed a retrospective analysis of all prostate biopsies performed at their institution between 1993 and 2005.
Of 1,607 biopsies performed, the percentage of positive biopsies and patient ages did not change significantly over time; however, there was a significant decrease in the median PSA level in patients undergoing biopsy and an increase in the median number of samples taken at the time of biopsy. In addition, fewer biopsies were performed on the basis of a suspicious digital rectal exam, and the percentage of patients undergoing biopsy for PSA readings between 2.5 and 3.99 ng/mL increased.
The positive biopsy rate in men with PSA levels in the 2.0 ng/mL to 3.99 ng/mL range equaled or surpassed that for patients with higher PSA readings.
“The correlation between PSA and positive biopsy rate no longer holds true in our patient population for men with a normal digital rectal exam and PSA >2.0 ng/mL,” according to lead author Douglas Scherr, MD.
The authors urged development of new blood or urinary markers to better determine who needs a prostate biopsy.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
Phase 1B trial to evaluate relugolix and enzalutamide in high-risk prostate cancer
July 24th 2024"Going forward after this study, we hope to be able to expand and potentially look at patients undergoing either surgery or radiation therapy, and really try to determine the potential benefit," says Kelly L. Stratton, MD, FACS.